Plethora Solutions Holdings

Plethora Solutions is a specialty pharmaceutical company focused on the development and marketing of products for the treatment of urological disorders, specifically male sexual health. The company's lead product is Fortacin (PSD502), a topical spray containing a combination of lidocaine and prilocaine designed to treat premature ejaculation. Fortacin has received marketing authorization in the European Union and is marketed in various territories through partnerships with companies like Recordati. In 2016, Plethora Solutions was acquired by Regent Pacific Group (now Endurance RP Limited) to expand its healthcare and life sciences portfolio. The company continues to seek regulatory approval for Fortacin in additional markets, including the United States.